Skip to main content
Premium Trial:

Request an Annual Quote

Decode, Thinner by 200 Staff, Pens Obesity R&D Collab With Merck

NEW YORK, Sept. 27 - Decode Genetics and Merck will partner to study the genetic components of obesity, the companies said today.

 

For the next three years, the two firms will use Decode's Clinical Gene Miner technology to hopefully gain a "detailed understanding" of targets provided through Merck's in-house gene-expression research.

Decode stands to pocket "substantial" research funding, tech-access and license fees, milestone payments, and potential royalties. Though none of the financial details was disclosed, Decode, which today announced it axed 200 employees, said it stands to earn $90 million if Merck is able to develop and sell "more than one" product from the collaboration.

 

Decode has already done some work in obesity. The Icelandic company said it has mapped "several key genes" linked to obesity, and has put together "detailed" genotypic and clinical data from more than 10,000 adult volunteers from its home country.

 

Click here for more information.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.